Options Commentary

It appears that the Olympics had a slight positive effect on Visa. The company’s foresight in backing swimmer Michael Phelps has earned an increase in their share price. Here are several option strategies on Visa to take advantage of this sponsorship potential.

Going Off the BoardI really, really, really wanted to title this section Harden My Heart, but I thought that I may get some nasty emails … so Ill put the Quarterflash reference in the text, which no one reads. Earlier today, U.S. health officials issued a warnings about a rare type of muscle inj

Energizing ResultsShares of Massey Energy are more than 5% higher this afternoon, thanks to the companys strong earnings report and forecast. Late yesterday, the Virginia-based company announced a second-quarter loss of $1.16 per share, but noted that a one-time charge of $245.3 million greatl

Its A Long Way to TysabriPharmaceutical firms are in the news today, as Amgen garnered early attention thanks to Fridays release of trial data. Other news attracting attention to the pharmaceutical sector may be released by Elan tomorrow. The firm is set to present midstage study data with W

Jumpin JuniperPlenty of news for Juniper Networks today, starting with the companys earnings report, which was released after the market closed last night. The company reported strong sales, which led to a 40% jump in second-quarter net income. The firm logged earnings of 28 cents per share

Looking for a company with heart? This weeks edition of Options Spotlight takes a look at Abiomed – a high-flying stock that continues to gain the attention of the bears. The medical instruments company developed a battery-powered, implantable replacement heart system called AbioCor, which

Banking on a Turnaround?Were having a bit of a delay in receiving the data that I use to pull our Options Update subject, so I sauntered over to my handy-dandy computer desktop and looked around for data from another source. Well, I definitely found activity that caught my eye. So lets take a l

Fair Scher of Negative ActionEarlier this morning, Merck and Schering-Plough announced that their second-quarter earnings reports would be delayed thanks to the later release of a study of Vytorin. The pharmaceutical has seen its sales suffer thanks to a controversial study showing it was